- Home
- COF vs BMY Comparison
COF vs BMY Comparison
Compare COF & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COF | BMY |
|---|---|---|
| Founded | 1988 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8B | 123.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | COF | BMY |
|---|---|---|
| Price | $178.41 | $57.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 16 |
| Target Price | ★ $273.93 | $61.81 |
| AVG Volume (30 Days) | 5.0M | ★ 9.7M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | 1.78% | ★ 4.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $96.05 | N/A |
| Revenue Next Year | $4.97 | N/A |
| P/E Ratio | $52.03 | ★ $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $143.22 | $42.52 |
| 52 Week High | $259.64 | $62.89 |
Technical Indicators
Market Signals| Indicator | COF | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 36.91 |
| Support Level | $176.36 | $53.88 |
| Resistance Level | $229.45 | $62.47 |
| Average True Range (ATR) | 4.55 | 1.22 |
| MACD | 0.37 | -0.52 |
| Stochastic Oscillator | 19.04 | 4.32 |
Price Performance
Historical ComparisonAbout COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending provides the majority of the bank's revenue.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.